Polarean and Philips Collaborate to Advance Pediatric Lung MRI Technology

Polarean Imaging ( (GB:POLX) ) has issued an update.

Polarean Imaging has announced a continued collaboration with Philips to expand the use of advanced Xenon lung MRI technology for children with chronic obstructive lung disease. This partnership is expected to enhance Polarean’s market position by broadening the application of its innovative imaging solutions, potentially benefiting stakeholders by addressing significant healthcare needs in pediatric respiratory medicine.

The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.

More about Polarean Imaging

Polarean Imaging is a medical imaging technology company specializing in advanced MRI techniques for lung function visualization. The company is a leader in hyperpolarisation science and has developed the FDA-approved XENOVIEW®, a hyperpolarised Xenon MRI inhaled contrast agent. With a focus on non-invasive, radiation-free pulmonary imaging, Polarean aims to address the global unmet needs of patients with chronic respiratory diseases.

Average Trading Volume: 2,063,616

Technical Sentiment Signal: Sell

Current Market Cap: £11.17M

For an in-depth examination of POLX stock, go to TipRanks’ Stock Analysis page.